Irinotecan Beyond Tumor Killing: A Gut–Liver Lens
2026-10-06
Irinotecan research is often framed around topoisomerase I inhibition, yet its effects also expose a clinically important gut–liver axis. This article interprets CPT-11 through that broader evidence framework, separating direct antitumor activity from chemotherapy-associated hepatic inflammation and outlining the translational limits of current models.
nor-NOHA: Evidence, Applications, and Limitations
2026-10-06
nor-NOHA is a reversible arginase inhibitor used in preclinical research on arginine metabolism, tumor-cell behavior, and vascular biology. Available product information reports effects in HepG2 cells and an arthritis-associated rat model, while a separate 2024 AML study describes a CD36-dependent lipid-immune pathway without testing nor-NOHA. This overview compares those evidence streams, clarifies what can and cannot be inferred, and identifies key translational limitations.
3-Deazaadenosine and the Methylation Control Point
2026-10-05
3-Deazaadenosine offers translational researchers a pathway-level lens on methylation biology, connecting S-adenosylhomocysteine hydrolase inhibition with antiviral and epitranscriptomic questions. This article interprets the compound’s research value alongside new evidence linking tristetraprolin, WTAP, m6A, and liver fibrosis while defining the limits of current evidence.
Nor-NOHA and the Next Frontier of Tumor Metabolism
2026-10-04
Nor-NOHA acetate offers a defined pharmacological lens on arginine metabolism, while recent AML research reveals how lipid sensing can reshape tumor–immune interactions. This thought-leadership analysis separates established findings from forward-looking hypotheses, positioning nor-NOHA as a mechanistic research probe rather than a validated AML therapy.
Potassium Phosphate Monobasic in Biological Buffers
2026-10-03
Potassium phosphate monobasic, or KH2PO4, is a water-compatible phosphate reagent used as an acid-side component in biological buffers. Its supplier specifications support identity and handling claims, while current drying literature does not establish it as a universal stabilizer for mRNA-lipid nanoparticles.
Cy5-UTP RNA Labeling: Workflow & Troubleshooting
2026-10-02
Cy5-UTP enables direct far-red detection of RNA made by T7 in vitro transcription, helping researchers move from probe synthesis to FISH, multiplex imaging, and expression profiling with fewer labeling steps. This guide connects the reagent to STAU2 condensate biology while emphasizing practical optimization, controls, and failure analysis.
Recombinant Mouse IFN-γ: Reliable Assays
2026-10-01
Learn how Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid), SKU P3167, can improve cytokine dosing, assay controls, and interpretation in mouse cell viability, proliferation, cytotoxicity, and antigen-presentation workflows. The article provides scenario-based guidance grounded in product specifications and recent MASH-HCC research.
Ibrexafungerp: Reliable Candida Assays
2026-10-01
This practical guide shows how Ibrexafungerp (SKU C8697) can support reproducible Candida susceptibility, viability, and translational infection workflows. It connects mechanism, assay design, quantitative C. auris evidence, protocol controls, and informed product selection.
Triamcinolone B1859: Practical Research Workflow
2026-09-30
Triamcinolone (SKU B1859) provides a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solvent selection, stock preparation, storage, assay controls, and interpretation boundaries; the compound is for scientific research only and is not intended for diagnostic, therapeutic, or clinical use.
CD36 Lipid Signaling and Immune Escape in AML
2026-09-30
A 2024 Cell Reports Medicine study identifies a non-canonical CD36 lipid-sensing pathway that enables AML cells to suppress T-cell activity and reduce the efficacy of decitabine. The work links oxidized LDL, palmitate, TLR4–LYN–MYD88–NF-κB signaling, and lipid-restriction strategies, providing a mechanistic framework for studying metabolic immune escape in AML.
3-Deazaadenosine hydrochloride in HSC assays
2026-09-29
Use 3-Deazaadenosine hydrochloride as an upstream S-adenosylhomocysteine hydrolase inhibitor to test whether methyl-metabolism pressure contributes to hepatic stellate cell activation. Pair it with IGF2BP1, TUBB4B, m6A, and FAK readouts to distinguish broad pathway dependence from gene-specific mechanisms.
CD36 Lipid Signaling Drives Immune Escape in AML
2026-09-29
Guo et al. show that AML cells use CD36 not only for lipid transport, but also as a signaling platform that integrates oxidized LDL and palmitate to suppress T-cell activity. The study identifies a CD36–TLR4–LYN–MYD88–NF-κB pathway and shows that statin-mediated lipid restriction can improve decitabine responses in experimental AML models.
Viral RIPK3 Degradation Shapes Orthopoxvirus Inflammation
2026-09-28
Liu and colleagues identify vIRD, an orthopoxvirus-encoded factor that recruits host ubiquitination machinery to promote proteasomal degradation of RIPK3 and suppress necroptosis. Viral genetics and mouse studies connect this pathway to orthopoxvirus replication, inflammation, and disease severity, while showing that the effect depends on RIPK3–MLKL signaling.
Decitabine: Immune-Priming Workflows in Tumor Models
2026-09-27
Learn how to test low-dose Decitabine as an immune-priming partner for anti–PD-1 therapy, with a workflow built around CD8+ progenitor exhausted T cells. Practical dose-selection, co-culture, readout, and troubleshooting guidance helps separate immune remodeling from nonspecific cytotoxicity.
nor-NOHA Workflows for AML and Cancer Research
2026-09-26
Use nor-NOHA to test whether arginase activity contributes to cancer-cell phenotypes or immune suppression, alongside—not in place of—CD36-focused experiments. This guide connects evidence from HepG2 and endothelial models to a carefully controlled, hypothesis-testing extension of AML immunometabolism research.